This presentation describes the new antimalarial formulation ASMQ (artesunate + mefloquine fixed-dose combination), including its ease of use, efficacy and tolerability, and clinical studies of its use in India and Brazil. In summary, it is efficacious, safe and well-tolerated, has a favourable pharmacokinetic profile and a simple regimen, and is a durable combination and a convenient coformulation with a 3-year shelf life. On the other hand it is not recommended in severe malaria, its use in pregnancy needs further study, and it shows cumulative toxicity with repeated dosing.
Presentation from ‘Artemisinin Combination Therapy (ACTs) in Myanmar: Status update and outlook’. Symposium held by DNDiii, Cipla and Vimal, Yangon, Myanmar (Rangoon, Burma), 24 January 2011.
New Partnerships The Development of ASMQ - FDC